Abstract

On the basis of scientific literature, there is growing evidence that KIM-1 and NGAL are interesting and promising biomarkers not only in acute and chronic inflammatory processes but also in oncogenesis. There are a number of studies which investigate their possible use in diagnosis, treatment and monitoring of therapy effectiveness. The results of recent research suggests that they may play an important role in standard oncology practice. Simultaneous measurement of KIM-1 and NGAL in urine can play a crucial role in carcinogenesis assessment and cancer progression. In the future, they can become rapid diagnostic indicators, which allow one to determine cancer subtype leading to biopsy replacement and therapy improvement. In the present work, beside biochemical characteristics of KIM-1 and NGAL, we will also discuss their role in the diagnosis and assessment of development of cancer.

References

• 1. Boekhorst B.C., Bovens S.M., Hellings W.E., van der Kraak P.H.,van de Kolk K.W., Vink A., Moll F.L., van Oosterhout M.F., de VriesJ.P., Doevendans P.A., Goumans M.J., de Kleijn D.P., van Echteld C.J.,Pasterkamp G., Sluijter J.P.: Molecular MRI of murine atheroscleroticplaque targeting NGAL: a protein associated with unstable humanplaque characteristics. Cardiovasc. Res., 2011; 89: 680-688
  Google Scholar
• 2. Bolignano D., Della Torre A., Lacquaniti A., Costantino G., FriesW., Buemi M.: Neutrophil gelatinase-associated lipocalin levels inpatients with crohn disease undergoing treatment with infliximab.J. Investig. Med., 2010; 58: 569-571
  Google Scholar
• 3. Bolignano D., Donato V., Coppolino G., Campo S., Buemi A., LacquanitiA., Buemi M.: Neutrophil gelatinase-associated lipocalin(NGAL) as a marker of kidney damage. Am. J. Kidney Dis., 2008; 52:595-606
  Google Scholar
• 4. Bolignano D., Donato V., Lacquaniti A., Fazio M.R., Bono C., CoppolinoG., Buemi M.: Neutrophil gelatinase-associated lipocalin (NGAL)in human neoplasias: a new protein enters the scene. Cancer Lett.,2010; 288: 10-16
  Google Scholar
• 5. Bonventre J.V.: Kidney injury molecule-1 (KIM-1): a urinary biomarkerand much more. Nephrol. Dial. Transplant., 2009; 24: 3765-3268
  Google Scholar
• 6. Bu D.X., Hemdahl A.L., Gabrielsen A., Fuxe J., Zhu C., Eriksson P.,Yan Z.Q.: Induction of neutrophil gelatinase-associated lipocalin invascular injury via activation of nuclear factor-κB. Am. J. Pathol.,2006; 169: 2245-2253
  Google Scholar
• 7. Candido S., Maestro R., Polesel J., Catania A., Maira F., SignorelliS.S., McCubrey J.A., Libra M.: Roles of neutrophil gelatinase-associatedlipocalin (NGAL) in human cancer. Oncotarget, 2014; 5: 1576-1594
  Google Scholar
• 8. Chakraborty S., Kaur S., Tong Z., Batra S.K., Guha S.: Neutrophilgelatinase associated lipocalin: structure. Neutrophil Gelatinase AssociatedLipocalin: Structure, Function and Role in Human Pathogenesis,Acute Phase Proteins – Regulation and Functions of AcutePhase Proteins, Prof. Francisco Veas (Ed.), ISBN: 978-953-307-252-4,InTech. http://www.intechopen.com/books/acute-phase-proteinsregulation-and-functions-of-acute-phase-proteins/neutrophil-gelatinase-associated-lipocalin-structure-function-and-role-in-humanpathogenesis(16.04.2015)
  Google Scholar
• 9. Clerico A., Galli C., Fortunato A., Ronco C.: Neutrophil gelatinaseassociatedlipocalin (NGAL) as biomarker of acute kidney injury:a review of the laboratory characteristics and clinical evidences.Clin. Chem. Lab. Med., 2012; 50: 1505-1517
  Google Scholar
• 10. Cuadros T., Trilla E., Sarró E., Vila M.R., Vilardell J., de TorresI., Salcedo M., López-Hellin J., Sánchez A., Ramón y Cayal S., ItarteE., Morote J., Meseguer A.: HAVCR/KIM-1activates the IL-6/STAT–3Pathway in ccRCC and Determines Tumor Progression and PatientOutcome. Cancer Res., 2014; 74: 1416-1428
  Google Scholar
• 11. Di Carlo A.: The enigmatic role of lipocalin 2 in human cancer.The multifunctional protein neutrophil gelatinase-associated lipocalin(NGAL) and its ambiguous role in human neoplasias, Prevent Res.,Public. 2012; 12. http://www.preventionandresearch.com/the-enigmatic-role-of-lipocalin-2-in-human-cancer-the-multifunctionalprotein-neutrophil-gelatinase-associated-lipocalin-ngal-and-itsambiguous-role-in-human-neoplasias.html (24.03.2015)
  Google Scholar
• 12. Fontanilla J., Han W.K.: Kidney injury molecule-1 as an earlydetection tool for acute kidney injury and other kidney disease.Expert Opin. Med. Diagn., 2011; 5: 161-173
  Google Scholar
• 13. Gala-Błądzińska A., Kuźniewski M.: Performance neutrophilgelatinase-associated lipocalin in clinical settings. Przegląd Lek.,2013; 70: 400-403
  Google Scholar
• 14. Grigoryev D., Liu M., Hassoun H., Cheadle C., Barnes K., RabbH.: The local and systemic inflammatory transcriptome after acutekidney injury. J. Am. Soc. Nephrol., 2008; 19: 547-558
  Google Scholar
• 15. Guo L., Takino T., Endo Y., Domoto T., Sato H.: Shedding of kidneyinjury molecule-1 by membrane-type 1 matrix metalloproteinase.J. Biochem., 2012; 152: 425-432
  Google Scholar
• 16. Han W.K., Bailly V., Abichandani R., Thadhani R., Bonventre J.V.:Kidney injury molecule-1 (KIM-1): a novel biomarker for human renalproximal tubule injury. Kidney Int., 2002; 62: 237-244
  Google Scholar
• 17. Hvidberg V., Jacobsen C., Strong R.K., Cowland J.B., MoestrupS.K., Borregaard N.: The endocytic receptor megalin binds the irontransporting neutrophil-gelatinase-associated lipocalin with highaffinity and mediates its cellular uptake. FEBS Lett., 2005; 579: 773-777
  Google Scholar
• 18. Ichimura T., Asseldonk E.J., Humphreys B.D., Gunaratnam L.,Duffield J.S., Bonventre J.V.: Kidney injury molekule-1 is a phosphatidylserinereceptor that confers a phagocytic phenotype onepithelial cells. I. Clin. Invest., 2008; 118: 1657-1668
  Google Scholar
• 19. Kuligowska-Prusińska M., Odrowąż-Sypniewska G.: NGAL jakonowy marker w diagnostyce chorób nerek. Abbott Voice, 2009; 20:8-12
  Google Scholar
• 20. Lee E.K., Kim H.J., Lee K.J., Lee H.J., Lee J.S., Kim D.G., Hong S.W.,Yoon Y., Kim J.S.: Inhibition of the proliferation and invasion of hepatocellularcarcinoma cells by lipocalin 2 through blockade of JNKand PI3K/Akt signaling. Int. J. Oncol., 2011; 38: 325-333
  Google Scholar
• 21. Lee H.J., Lee E.K., Lee K.J., Hong S.W., Yoon Y., Kim J.S.: Ectopicexpression of neutrophil gelatinase-associated lipocalin suppressesthe invasion and liver metastasis of colon cancer cells. Int. J. Cancer,2006; 118: 2490-2497
  Google Scholar
• 22. Lim R., Ahmed N., Borregaard N., Riley C., Wafai R., ThompsonE.W., Quinn M.A., Rice G.E.: Neutrophil gelatinase-associated lipocalin(NGAL) an early-screening biomarker for ovarian cancer: NGALis associated with epidermal growth factor-induced epithelio-mesenchymaltransition. Int. J. Cancer, 2007; 120: 2426-2434
  Google Scholar
• 23. Lin F., Zhang P.L., Yang X.J., Shi J., Blasick T., Han W.K., Wang H.L.,Shen S.S., Teh B.T., Bonventre J.V.: Human kidney injury molecule-1(hKIM-1): a useful immunohistochemical marker for diagnosingrenal cell carcinoma and ovarian clear cell carcinoma. Am. J. Surg.Pathol., 2007; 31: 371-381
  Google Scholar
• 24. Lisowska-Myjak B.: Laboratoryjne wskaźniki ostrego uszkodzenianerek oznaczane w moczu i w surowicy. Forum Nefrologiczne,2010; 3: 71-81
  Google Scholar
• 25. Malyszko J., Koc-Zorawska E., Malyszko J.S., Mysliwiec M.: Kidneyinjury molecule-1 correlates with kidney function in renal allograftrecipients. Transplant. Proc., 2010; 42: 3957-3959
  Google Scholar
• 26. Marchewka Z.: Niskocząsteczkowe wskaźniki biochemiczne w diagnostycenefrotoksyczności. Adv. Clin. Exp. Med., 2006; 15: 1129-1138
  Google Scholar
• 27. Marchewka Z., Płonka J.: Znaczenie diagnostyczne nowego markeraKIM-1 w uszkodzeniach nerek. Postępy Hig. Med. Dośw., 2013;67: 695-699
  Google Scholar
• 28. Monier F., Mollier S., Guillot M., Rambeaud J., Morel F., ZaouiP.: Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL andconventional prognostic factors in urothelial carcinomas. Eur. Urol.,2002; 42: 356-363
  Google Scholar
• 29. Monisha J., Padmavathi G., Bordoloi D., Roy N.K., KunnumakkaraA. B.: Neutrophil gelatinase – associated lipocalin (NGAL): A promisingbiomarker for cancer diagnosis and a potential target for cancertherapeutics. J. Cell. Sci. Molecul. Biol., 2014; 1: 106
  Google Scholar
• 30. Poczęta M., Bednarek I.: STAT-3 ukryty czynnik transkrypcyjnycelem terapii przeciwnowotworowej. Ann. Acad. Med. Siles., 2013;67: 133-141
  Google Scholar
• 31. Radosz A., Obuchowicz A.: Potential diagnostic significance ofneutrophil gelatinase-associated lipocalin. Ann. Acad. Med. Siles.,2013; 67: 61-66
  Google Scholar
• 32. Sabbisetti V.S., Waikar S.S., Antoine D.J., Smiles A., Wang C.,Ravisankar A., Ito K., Sharma S., Ramadesikan S., Lee M., Briskin R.,De Jager P.L., Ngo T.T., Radlinski M., Dear J.W., Park K.B., BetenskyR., Krolewski A.S., Bonventre J.V.: Blood kidney injury molecule-1 isa biomarker of acute and chronic kidney injury and predicts progressionto ESRD in type I diabetes. J. Am. Soc. Nephrol., 2014; 25:2177-2186
  Google Scholar
• 33. Schmidt-Ott K.M., Mori K., Li J.Y., Kalandadze A., Cohen D.J., DevarajanP., Barasch J.: Dual action of neutrophil gelatinase-associatedlipocalin. J. Am. Soc. Nephrol., 2007; 18: 407-413
  Google Scholar
• 34. Shalabi A., Abassi Z., Awad H., Halachmi S., Moskovitz B., KlugerY., Nativ O.: Urinary NGAL and KIM-1: potential association with histopathologicfeatures in patients with renal cell carcinoma. WorldJ. Urol., 2013; 31: 1541-1545
  Google Scholar
• 35. Tong Z., Chakraborty S., Sung B., Koolwal P., Kaur S., AggarwalB.B., Mani S.A., Bresalier R.S., Batra S.K., Guha S.: Epidermal growthfactor down-regulates the expression of neutrophil gelatinase-associatedlipocalin (NGAL) through E-cadherin in pancreatic cancercells. Cancer, 2011; 117: 2408-2418
  Google Scholar
• 36. Tong Z., Kunnumakkara A.B., Wang H., Matsuo Y., DiagaradjaneP., Harikumar K.B., Ramachandran V., Sung B., Chakraborty A., BresalierR.S., Logsdon C., Aggarwal B.B., Krishnan S., Guha S.: Neutrophilgelatinase-associated lipocalin: a novel suppressor of invasion andangiogenesis in pancreatic cancer. Cancer Res., 2008; 68: 6100-6108
  Google Scholar
• 37. Totoń E., Rybczyńska M.: Charakterystyka białka FAK i jego rolaw procesie nowotworzenia. Postępy Hig. Med. Dośw., 2007; 61: 303-309
  Google Scholar
• 38. Trof R.J., Di Maggio F., Leemreis J., Groeneveld A.B.: Biomarkersof acute renal injury and renal failure. Shock, 2006; 26: 245-253
  Google Scholar
• 39. Vaidya V.S., Ramirez V., Ichimura T., Bobadilla N.A., BonventreJ.V.: Urinary kidney injury molecule-1: a sensitive quantitative biomarkerfor early detection of kidney tubular injury. Am. J. Physiol.Renal. Physiol., 2006; 290: 517-529
  Google Scholar
• 40. Yang L., Brooks C.R., Xiao S., Sabbisetti V., Yeung M.Y., Hsiao L.L.,Ichimura T., Kuchroo V., Bonventre J.V.: KIM-1-mediated phagocytosisreduces acute injury to the kidney. J. Clin. Invest., 2015; 125:1620-1636
  Google Scholar
• 41. Zhang P.L., Mashni J.W., Sabbisetti V.S., Schworer C.M., WilsonG.D., Wolforth S.C., Kernen K.M., Seifman B.D., Amin M.B., Geddes T.J.,Lin F., Bonventre J.V., Hafron J.M.: Urine kidney injury molecule-1:a potential non-invasive biomarker for patients with renal cell carcinoma.Int. Urol. Nephrol., 2014; 46: 379-388
  Google Scholar

Full text